UNLABELLED: PRIMARY AIM: Examine the effectiveness of extended cognitive behavior therapy (CBT) in promoting longer-term smoking abstinence. DESIGN: Open-label treatment phase followed by extended treatment phase. Randomization conducted prior to entry into open-label treatment phase; analysis based on intention-to-treat to avoid threat of selection bias. SETTING:Community smoking cessation clinic. PARTICIPANTS: A total of 304 adult smokers (> or = 18 years of age; > or = 10 cigarettes/day). INTERVENTION: Open-label (8 weeks): all participants received bupropion SR, nicotine patch, CBT. Extended treatment (12 weeks): participants received either CBT + voicemail monitoring and telephone counseling or telephone-based general support. MEASUREMENTS: Seven-day point prevalence abstinence, expired-air carbon monoxide. RESULTS: At week 20 follow-up, CBT produced a higher 7-day point prevalence abstinence rate: 45% versus 29%, P = 0.006; at 52 weeks the difference in abstinence rates (31% versus 27%) was not significant. History of depression was a moderator of treatment. Those with a positive history had a better treatment response at 20 weeks when assigned to the less intensive telephone support therapy (P < 0.05). CONCLUSION: The superiority of CBT to 20 weeks suggests that continued emphasis on the development of cognitive and behavioral strategies for maintaining non-smoking during an extended treatment phase may help smokers to maintain abstinence in the longer term. At present, the minimum duration of therapy is unknown.
RCT Entities:
UNLABELLED: PRIMARY AIM: Examine the effectiveness of extended cognitive behavior therapy (CBT) in promoting longer-term smoking abstinence. DESIGN: Open-label treatment phase followed by extended treatment phase. Randomization conducted prior to entry into open-label treatment phase; analysis based on intention-to-treat to avoid threat of selection bias. SETTING: Community smoking cessation clinic. PARTICIPANTS: A total of 304 adult smokers (> or = 18 years of age; > or = 10 cigarettes/day). INTERVENTION: Open-label (8 weeks): all participants received bupropion SR, nicotine patch, CBT. Extended treatment (12 weeks): participants received either CBT + voicemail monitoring and telephone counseling or telephone-based general support. MEASUREMENTS: Seven-day point prevalence abstinence, expired-air carbon monoxide. RESULTS: At week 20 follow-up, CBT produced a higher 7-day point prevalence abstinence rate: 45% versus 29%, P = 0.006; at 52 weeks the difference in abstinence rates (31% versus 27%) was not significant. History of depression was a moderator of treatment. Those with a positive history had a better treatment response at 20 weeks when assigned to the less intensive telephone support therapy (P < 0.05). CONCLUSION: The superiority of CBT to 20 weeks suggests that continued emphasis on the development of cognitive and behavioral strategies for maintaining non-smoking during an extended treatment phase may help smokers to maintain abstinence in the longer term. At present, the minimum duration of therapy is unknown.
Authors: Brian Hitsman; George D Papandonatos; Dennis E McChargue; Andrew DeMott; María José Herrera; Bonnie Spring; Belinda Borrelli; Raymond Niaura Journal: Addiction Date: 2013-02 Impact factor: 6.526
Authors: Steffani R Bailey; Sarah A Hagen; Christina J Jeffery; Christopher T Harrison; Seth Ammerman; Susan W Bryson; Diana T Killen; Thomas N Robinson; Joel D Killen Journal: Nicotine Tob Res Date: 2013-03-04 Impact factor: 4.244
Authors: Sharon M Hall; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Judith J Prochaska; Julie A Robbins Journal: Am J Public Health Date: 2011-06-08 Impact factor: 9.308
Authors: Megan E Piper; Tanya R Schlam; Jessica W Cook; Stevens S Smith; Daniel M Bolt; Wei-Yin Loh; Robin Mermelstein; Linda M Collins; Michael C Fiore; Timothy B Baker Journal: Drug Alcohol Depend Date: 2016-11-25 Impact factor: 4.492
Authors: Ronnesia B Gaskins; Ernestine G Jennings; Herpreet Thind; Joseph L Fava; Santina Horowitz; Ryan Lantini; Bruce M Becker; Beth C Bock Journal: Transl Behav Med Date: 2015-06 Impact factor: 3.046
Authors: Sharon M Hall; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Julie A Robbins; Judith J Prochaska Journal: Addiction Date: 2009-04-09 Impact factor: 6.526